NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Ascendis Pharma A/S (ASND) Stock Analysis

Ascendis Pharma A/S (ASND) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ASND

$238.90

+$4.57 (+1.95%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ASND with… →

ASND Key Statistics

As of Oct 21, 2026
Trading
Open
$236.00
Previous Close
$234.33
Day's Range
235.82–240.21
52-Week Range
188.07–282.15
Volume
662.04K
Valuation
Market Cap
$15.72B
P/E Ratio
17.98
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
22.15
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
15.01
EPS (ttm)Profit attributable to each share over the last twelve months.
13.29
Financials (FY)
Revenue (FY)
$720.13M+98.03%
Net Income (FY)
−$228.03M
Profit marginThe share of revenue left as profit after all costs and taxes.
70.85%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
65.80M
1-Year Return
+19.10%
Dividend and dates
Avg Volume
688.80K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ASND closed at $238.90, +19.10% over 1 year.

Ascendis Pharma A/S (ASND) has a market capitalization of $15.72B.

In fiscal 2025, ASND reported revenue of $720.13M.

ASND Stock Return by Calendar Year

Ascendis Pharma A/S (ASND) 10-year return: what $10,000 became

1 year
$10,000 $11,910
+19.10%
5 years
$10,000 $16,406
+64.06%
10 years
$10,000 $125,210
+1,152.10%

If you had invested $10,000 in Ascendis Pharma A/S (ASND) 10 years ago, at the close on October 21, 2016, it would have been worth $125,210 at the close on October 21, 2026: +1,152.10% in total, +28.75% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+12.03%
2025+54.89%
2024+9.31%
2023+3.13%
2022−9.22%
2021−19.34%
2020+19.88%
2019+122.06%
2018+56.39%
2017+97.92%
2016 (partial year)+40.56%

As of October 21, 2026.

ASND Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$720.13M−$228.03M−31.7%
2024$363.64M−$378.08M−104.0%
2023$266.72M−$481.45M−180.5%
2022$51.17M−$583.19M−1,139.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$720.13M$625.22M−$136.27M−$228.03M−31.7%
2024$363.64M$319.38M−$278.76M−$378.08M−104.0%
2023$266.72M$222.32M−$455.54M−$481.45M−180.5%
2022$51.17M$39.04M−$561.81M−$583.19M−1,139.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ASND Valuation vs Biotechnology Median

Median of 608 stocks
MetricASNDBiotechnology medianvs median
P/E17.9816.608% above
P/S ratio15.0113.3013% above
Profit margin70.85%−38.31%109.2 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Ascendis Pharma A/S (ASND) carries a market capitalisation of $15.72B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 1,189 employees.

The 52-week range on file runs from $188.07 to $282.15. ASND last closed at $238.90 on October 21, 2026. That is +$4.57 (+1.95%) against the previous close. The latest close sits 27.03% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $720.13M. That is +98.03% against the prior fiscal year, when revenue was $363.64M. The same year closed with a net loss of $228.03M. The reported profit margin is 70.85%. That is 109.2 percentage points above the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to 13.29.

Across the 4 fiscal years on file, revenue moves from $51.17M in 2022 to $720.13M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 17.98 times earnings. That is 8.31% above the Biotechnology median of 16.6. On forward earnings the ratio is 22.15. Measured against sales, the shares trade at 15.01 times revenue. On price-to-sales that is 12.9% above the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is +19.10%. Measured over 10 years, that is +28.75% a year compounded. Daily returns over the trailing 10 years annualize to a volatility of 50.88%.

Growth & Income

The record shows no dividend for ASND.

So far in 2026 the total return is +12.03%. Across the complete calendar years on file, 2019 returned +122.06% and 2021 returned −19.34%. Of the 9 complete calendar years on file, 7 finished higher.

Peer Comparison

Ascendis Pharma A/S (ASND) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Ascendis Pharma A/S ASND $15.72B 18.0
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Ascendis Pharma A/S trades at a P/E of 18.0.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Ascendis Pharma A/S

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Visit website →